Regenxbio Inc (RGNX.OQ)
39.10USD
19 Apr 2018
$-1.40 (-3.46%)
$40.50
$40.50
$41.70
$38.80
193,206
116,316
$41.95
$16.30
Latest Key Developments (Source: Significant Developments)
Regenxbio Inc Q4 Loss Per Share $0.51
March 6 (Reuters) - Regenxbio Inc
Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments
Jan 8 (Reuters) - Avexis Inc
Regenxbio Provides Year-End 2017 Corporate Update
Jan 4 (Reuters) - Regenxbio Inc
Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II
Dec 19 (Reuters) - Regenxbio Inc
Regenxbio reports third quarter financial results
Nov 8 (Reuters) - Regenxbio Inc
RTW Investments reports 5 pct passive stake in Regenxbio
Oct 5 (Reuters) - RTW Investments:RTW Investments reports a 5 percent passive stake in Regenxbio Inc as of October 2, 2017 - SEC filing. Full Article
Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 mln-SEC filing
Oct 3 (Reuters) - Dimension Therapeutics Inc
Ultragenyx Pharmaceutical comments on Dimension Therapeutics' announcement
Oct 2 (Reuters) - Ultragenyx Pharmaceutical: :Ultragenyx Pharmaceutical comments on dimension therapeutics' announcement that co's offer is a "superior proposal" in its merger agreement with regenxbio.Ultragenyx Pharmaceutical says is "pleased" that dimension board determined that all-cash offer to buy dimension for $6.00 per share is a superior proposal. Full Article
Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD
Sept 20 (Reuters) - Regenxbio Inc
Dimension Therapeutics to pay $2.9 mln to Regenxbio incase merger terminates
Aug 25 (Reuters) - Dimension Therapeutics Inc
BRIEF-Regenxbio Inc Q4 Loss Per Share $0.51
* REGENXBIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS